

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
Name	Execution Date
Addrenex Pharmaceuticals, Inc.	05/03/2010
<b>RECEIVING PARTY DATA</b>	
Name:	Shionogi Pharma, Inc.
Street Address:	Five Concourse Parkway
Internal Address:	Suite 1800
City:	Atlanta
State/Country:	GEORGIA
Postal Code:	30328
<b>PROPERTY NUMBERS Total: 1</b>	
Property Type	Number
Application Number:	12615477
<b>CORRESPONDENCE DATA</b>	
Fax Number:	(919)854-1401
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	919-854-1400
Email:	msalazar@myersbigel.com
Correspondent Name:	MBSS / Marthenn Salazar
Address Line 1:	4140 Parklake Ave
Address Line 2:	Suite 600
Address Line 4:	Raleigh, NORTH CAROLINA 27612
ATTORNEY DOCKET NUMBER:	9726-11CT2
NAME OF SUBMITTER:	Marthenn Salazar

Total Attachments: 5  
 source=assignmentAddrenex#page1.tif  
 source=assignmentAddrenex#page2.tif

**501184359**

**PATENT  
 REEL: 024427 FRAME: 0085**

**CH \$40.00 12615477**

source=assignmentAddrenex#page3.tif  
source=assignmentAddrenex#page4.tif  
source=assignmentAddrenex#page5.tif

## ASSIGNMENT

THIS ASSIGNMENT, made by **Addrenex Pharmaceuticals, Inc.**, a Delaware corporation having a principal place of business at 4825 Creekstone Dr., Suite 100, Durham, NC 27703-8051, hereinafter referred to as assignor;

WITNESSETH; That,

WHEREAS the above named corporation is the owner of the entire right, title, and interest in and to the U.S. patents and patent applications set forth in Schedule A attached hereto, and all rights therein provided by international conventions or treaties, and the inventions disclosed and claimed therein, and any applications that rely on one or more of the patents and patent applications set forth in Schedule A for priority, including with respect to all of the foregoing, any and all divisionals, continuations, continued prosecution applications, continuations-in-part, reissues, reexaminations thereof, as well as Patent Cooperation Treaty counterparts thereof, as set forth in Schedule B attached hereto, together with all patents issuing on any of the aforesaid applications for a patent (collectively the "Patents and Applications");

WHEREAS **Shionogi Pharma, Inc.**, a Delaware corporation, having a place of business at Five Concourse Parkway, Suite 1800, Atlanta, GA 30328, hereinafter referred to as assignee, is desirous of acquiring the assignor's entire right, title, and interest in and to said Patents and Applications;

NOW, THEREFORE, To All Whom It May Concern, be it known that for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the above assignor has sold and by these presents does hereby sell, assign, transfer, and convey unto the said assignee, its successors and assigns, its entire right, title, and interest in and to said Patents and Applications, for the full term for which said Patents and Applications may be granted, along with any term extensions thereon or therefor, together with the right to claim the priority of said Patents and Applications in all foreign countries in accordance with the international conventions or treaties, the same to be held and enjoyed by said assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by assignor if this assignment and sale had not been made.

The assignor further covenants and agrees that, at the time of the execution and delivery of these presents, it possesses full title to said Patents and Applications, and that it has the unencumbered right and authority to make this assignment.

Assignment

Addrenex Pharmaceuticals, Inc. to Shionogi Pharma, Inc.

WHEREBY **Shionogi Pharma, Inc.** acknowledges and accepts the assignment;

IN WITNESS WHEREOF, I have hereunto set my hand and seal on this 3 day of MAY, 2010. The undersigned warrants and represents that he/she has the authority to sign this Assignment on behalf of the Assignee, **Shionogi Pharma, Inc.**

By: Leslie B. Zacks (SEAL)  
Name

LESLIE B. ZACKS (PRINT)  
Name

EV, LEGAL + COMPLIANCE  
Title

WITNESS: James Corbit (JAMES CORBITT)

DATE: May 3, 2010

WITNESS: Hardy Garner

DATE: May 3, 2010

Assignment


Addrenex Pharmaceuticals, Inc. to Shionogi Pharma, Inc.

The assignor further covenants and agrees to promptly communicate to said assignee or its representatives any facts known to the assignor relating to said invention, to testify in any interference or legal proceedings involving said invention, to execute any additional papers which may be requested to confirm the right of the assignee, its representatives, successors, or assigns to secure patent or similar protection for the said invention in all countries and to vest in the assignee complete title to the said Patents and Applications.

IN WITNESS WHEREOF, the assignor has caused this assignment to be executed at

Atlanta, Georgia this 3 day of May, 2010.

For: **ADDRENEX PHARMACEUTICALS, INC.**


By:  (SEAL)  
Name

DARRELL BORNE (PRINT)  
Name

CFO  
Title

WITNESS:  (JAMES CORBIT)

DATE: May 3, 2010

WITNESS: 

DATE: May 3, 2010

Assignment

Addrenex Pharmaceuticals, Inc. to Shionogi Pharma, Inc.

<b>SCHEDULE -- A --</b>		
<b>United States Patent Applications</b>		
<b>Attorney Docket</b>	<b>Application Number</b>	<b>Filing Date</b>
9726-10	08/136,309	October 13, 1993
9726-10CT	08/566,837	December 4, 1995
9726-10CT2	08/884,283	June 27, 1997
9726-10DV	08/556,916	December 4, 1995
9726-10DVCT	08/881,314	June 24, 1997
9726-11PR	60/942,934	June 8, 2007
9726-11	12/134,444	June 6, 2008
9726-11CT	12/560,648	September 16, 2009
9726-11CT2	12/615,477	November 10, 2009
9726-18PR	61/219,082	June 22, 2009
9726-19PR	61/236,647	August 15, 2009

Assignment

Addrenex Pharmaceuticals, Inc. to Shionogi Pharma, Inc.

<b>SCHEDULE - B -</b>		
<b>Patent Cooperation Treaty Applications</b>		
<b>Attorney Docket</b>	<b>PCT Application Number</b>	<b>Filing Date</b>
9726-10WO	PCT/US95/001029	January 26, 1995
9726-11WO	PCT/US08/066036	June 6, 2008